Efforts to understand how cancer immunotherapy restores anti-tumor T cell responses have largely concentrated on assessing the reactivation of dysfunctional T cells. In this issue of Immunity, Kurtulus et al. (2019) and Siddiqui et al. (2019) provide evidence that durable anti-tumor responses require less differentiated T cells that express the transcription factor Tcf1 and sustain the tumor-reactive T cell pool.

中文翻译：

---

首先（最后）：了解免疫疗法中的持久性T细胞反应

理解癌症免疫疗法如何恢复抗肿瘤T细胞反应的努力主要集中在评估功能异常T细胞的重新激活上。在本期《免疫》中，Kurtulus等人。（2019）和Siddiqui等。（2019）提供的证据表明，持久的抗肿瘤反应需要表达转录因子Tcf1并维持肿瘤反应性T细胞库的分化程度较低的T细胞。